Medical Translation Services Singapore
Singapore produces 6% of the world's over-the-counter drugs and is a leading Asia-Pacific hub for pharmaceutical manufacturing, clinical trials, and medical device registration. The clinical trial data supporting most HSA drug registrations comes from Japan, China, and Korea. The ICH CTD dossier that carries it must be in English. The translators who bridge that gap are not generalists — they are life scientists who also translate.
Singapore produces 6% of the world's OTC drugs. Its HSA is one of Asia's most respected regulatory authorities. When clinical data travels from Japan, China, or Korea to HSA — it must be translated by someone who understands both the language and the science.
Singapore's pharmaceutical sector is not primarily domestic. It is a global manufacturing and regulatory hub — a place where multinational pharma companies register drugs across Southeast Asia, conduct regional clinical trials, and submit dossiers that draw on studies from Japan, China, Korea, and the United States. At the intersection of every foreign clinical study and every HSA review is a translation that either accurately represents the science or does not. The downstream consequences of the latter range from delayed registration to patient harm.
The ICH Common Technical Document — the five-module structure that governs every HSA drug registration, and where translation is most critical
HSA requires drug registration dossiers in the ICH CTD or ACTD format, submitted via the PRISM portal. From April 2026, eCTD submissions via HSA's new portal will also be accepted. The CTD has five modules — each with distinct translation demands. The translation burden is highest in Module 5, which contains the clinical data that makes or breaks a registration.
Module 1 — Administrative & Prescribing Information
Regional administrative information, product labelling (Patient Information Leaflet, PIL), prescribing information, package insert. The PIL is patient-facing — it must be accurate, clear, and available in English and, for Singapore, often in Mandarin for Chinese-speaking patients. Dosage instructions and contraindications in the PIL are the highest-risk items for direct patient harm if mistranslated.
Module 2 — Overviews & Summaries
Written and tabulated summaries of quality, non-clinical, and clinical data. This is the module HSA reviewers read first to understand the overall profile of the drug. If the summaries are derived from Japanese or Chinese original documents, accurate translation is essential — this is where the reviewer forms their initial assessment of benefit-risk.
Module 3 — Quality (Chemistry, Manufacturing & Controls)
Manufacturing process, specifications, analytical methods, stability data. Pharmaceutical chemistry and manufacturing terminology is highly technical — synthesis route descriptions, excipient specifications, dissolution parameters. Japanese and Korean pharmaceutical CMC documents use a precise technical vocabulary that requires translators with pharmaceutical chemistry training.
Module 4 — Non-Clinical (Pharmacology, Toxicology)
Pharmacology, pharmacokinetics, and toxicology study reports. These are typically conducted under GLP conditions and reported in the sponsor's home language — for Japanese innovators, Japanese; for Chinese companies, Chinese. HSA reviewers need accurate English translation to assess the non-clinical safety profile. Adverse effect terminology in animal studies must be rendered with precision.
Module 5 — Clinical Data (Efficacy & Safety Studies)
Clinical study reports, individual patient data summaries, adverse event listings, pharmacovigilance data, literature references. This is the largest and most consequential module. Clinical trials for drugs registered in Singapore are frequently conducted in Japan, China, or Korea — and the data arrives in Japanese, Chinese, or Korean. Module 5 translation requires a life scientist who understands ICH E3 clinical study report structure, MedDRA adverse event terminology, and the clinical significance of what they are translating. This is the highest-volume medical translation category for Singapore HSA submissions.
HSA eCTD update: HSA launched its eCTD test submission portal on 30 September 2025. The portal accepts live dossier submissions from 1 April 2026. All submissions must follow ICH eCTD specification 3.2.2 and the SG-HSA eCTD Specification package v1.0 (published September 2024). Translated documents submitted in eCTD format must be text-searchable PDFs — scanned translations are not accepted.
The four main medical translation categories for Singapore — and what each requires
Pharmaceutical Regulatory Submissions
Clinical Trials (HSA CTA/CTN/CTC)
Medical Devices (Class C & D Registration)
Patient-Facing & Clinical Practice
The specific failure modes that make medical translation more consequential than most professional translation
Dosage instructions: A patient information leaflet for a paediatric antibiotic was translated from Chinese to English. The original specified "每日两次，每次5毫升" — twice daily, 5ml per dose. The translator rendered it as "twice daily, 5mg per dose." The unit error went undetected through review. In a paediatric context, a dosage unit confusion between mg (by weight) and ml (by volume) for a liquid antibiotic creates a real risk of under- or over-dosing — outcomes that range from treatment failure to toxicity. A unit confusion is not a minor translation error. It is a patient safety event.
Adverse event terminology: In Japanese clinical trial reporting, the MedDRA preferred term "神経過敏" (shinkei kabin) is correctly translated as "nervousness" — a MedDRA Grade 1–2 term. But "興奮" (koufun, meaning excited/agitated) in the same context might be rendered as "excitement," when the clinical context clearly means "agitation" — a more severe MedDRA term with different reporting implications. The distinction between nervousness and agitation in an adverse event listing can affect whether a drug's safety profile triggers additional regulatory review.
Contraindication omission: A Japanese-origin drug label contained a contraindication specific to patients with a history of hepatic impairment — clearly stated in the Japanese original. A non-specialist translation team, working at volume, rendered the surrounding paragraph but missed the contraindication clause. The English PIL went through several rounds of review without anyone identifying the gap, because the reviewers were working from the English version and had no access to the Japanese original. The drug was registered. The contraindication omission was identified in a post-market pharmacovigilance audit 18 months later.
Our medical translators hold undergraduate or postgraduate degrees in pharmacology, biochemistry, medicine, nursing, or a related life sciences field. They are trained in MedDRA terminology, ICH CTD structure, and the specific regulatory frameworks of the source country. The ISO 17100 two-linguist review means a second medically qualified translator checks every submission before delivery.
The primary clinical trial and drug development languages in Singapore HSA submissions — and the specific challenges each presents
| Language | Regulatory Context | Key Translation Challenges | Typical Documents |
|---|---|---|---|
| 🇯🇵 Japanese | Japan is a global pharmaceutical innovator. PMDA (Japan's FDA equivalent) is one of HSA's reference agencies. Many drugs registered in Singapore originate from Japanese companies. | Japanese medical Japanese uses classical Chinese-character compounds for anatomical and disease terminology that have no direct English equivalent. MedDRA Japanese coding uses MEDDRA-J, which differs from the ICH MedDRA in subtle ways that affect adverse event translation. Japanese clinical study reports follow PMDA-specific structural conventions. | CTD Module 5 CSRs, PMDA approval documents, package inserts (添付文書), adverse event tables (有害事象) |
| 🇨🇳 Chinese (Simplified) | NMPA (China's drug regulator) follows ICH guidelines, creating alignment but not identity with HSA requirements. Chinese pharmaceutical manufacturers are significant exporters to Singapore's formulation sector. | Chinese clinical trial data may use CTCAE terminology adapted into Chinese — the mapping back to English CTCAE/MedDRA must be precise. Chinese CMC documents for chemical synthesis use IUPAC naming conventions in Chinese that require chemistry-trained translators. Traditional Chinese Medicine (TCM) terms require careful contextualisation for Western regulatory frameworks. | CTD Module 3 quality docs, clinical study reports, GMP inspection reports (GMP证书), drug registration certificates (注册证) |
| 🇰🇷 Korean | MFDS (Korea's FDA equivalent) is not yet an HSA reference agency, but Korean pharmaceutical companies — including Samsung Biologics, Celltrion, and Yuhan Corporation — are active in Singapore's market. | Korean medical terminology uses a mixture of Sino-Korean compounds (Hanja-based) and loan words from English. The same adverse event can be described using either system within the same document. Korean clinical study reports follow MFDS-specific formats that differ from ICH CTD in structural conventions and section numbering. | Korean NDA supporting documents, CSRs for biosimilar applications, device conformity assessments (의료기기), labelling translations (Korean ↔ English) |
| 🇮🇩 Bahasa Indonesia | Indonesia's BPOM is the counterpart authority in the region. Indonesian pharmaceutical and medical device companies seeking Singapore registration submit supporting documentation in Bahasa. | Indonesian regulatory documents use a formal Bahasa register distinct from everyday Bahasa. BPOM-specific terminology for drug categories (Obat Keras, Obat Bebas Terbatas) must be contextualised against Singapore's Prescription Only Medicine, Pharmacy Only, GSL classification system. | BPOM registration certificates, Indonesian clinical data supporting HSA submissions, medical device conformity documents |
What pharmaceutical companies, CROs, and medical device manufacturers need from a translation partner for Singapore
Life sciences qualifications required
All medical translators hold a degree in pharmacology, biochemistry, medicine, nursing, or a related field. Language competence alone is not sufficient — they must understand what they are translating scientifically. A translator who cannot distinguish between an adverse event severity grade and a drug interaction mechanism should not be translating clinical study reports.
MedDRA and ICH terminology trained
Our medical translators use MedDRA preferred terms consistently — they do not invent English equivalents for adverse events. For ICH CTD submissions, terminology is standardised across the dossier using a module-specific glossary. A preferred term that differs between Module 2 summaries and Module 5 patient data listings will be identified and aligned before delivery.
ISO 17100 two-linguist review — HSA-appropriate
Every pharmaceutical translation is reviewed by an independent second medically qualified linguist. For HSA regulatory submissions, this review checks terminology consistency throughout the dossier, not just accuracy sentence by sentence. A translation that is accurate at sentence level but uses inconsistent terminology across modules creates confusion for HSA reviewers.
NDA and IP protection as standard
Pre-approval pharmaceutical data is highly commercially sensitive. Compound identities, trial results, manufacturing processes — all of these carry IP value and regulatory exclusivity implications. Every translator, reviewer, and project manager signs an NDA before receiving any pharmaceutical materials. We do not use translation memory systems that retain compound names across unrelated client engagements.
Regulatory submission deadlines
HSA has review timelines. Missing a submission window can delay product registration by months — with direct commercial and patient-access consequences. We work with your regulatory affairs team's submission schedule from the start of each engagement, and confirm whether volume-based deadlines are achievable before accepting the work.
Back-translation for patient-facing documents
ICH E6 GCP requires patient-facing documents — particularly Informed Consent Forms for clinical trials — to be validated by back-translation. We provide both the translation and the independent back-translation, and prepare the reconciliation report comparing the two, as required for IRB/EC approval documentation for Singapore clinical trial applications.
Medical translation Singapore — frequently asked questions
Related services
Patent Translation Singapore
IPOS/PCT pharmaceutical patent claims — the technical counterpart to drug registration. A mistranslated patent claim is as costly as a mistranslated drug label.
Explore →Chinese Business Translation
Chinese pharmaceutical and medical device companies entering Singapore. Contracts, corporate governance documents, regulatory authority correspondence.
Explore →Legal Translation
Pharmaceutical licensing agreements, clinical trial agreements, IP assignments. Medical translation and legal translation overlap significantly in the pharma sector.
Explore →Medical or pharmaceutical translation for Singapore?
Email your document type, language pair, and submission deadline. For HSA regulatory submissions, we confirm translator qualifications for your specific therapeutic area before accepting the instruction.
medical translation services Singapore · HSA translation Singapore · pharmaceutical translation Singapore · clinical trial translation Singapore · medical document translation Singapore · drug registration translation Singapore · CTD translation Singapore · eCTD translation Singapore · patient information translation Singapore · ICH GCP translation Singapore · MedDRA translation Singapore · healthcare translation Singapore · professional translation Singapore · translation services Singapore